Chronic nasal congestion, rhinitis, can be caused by excessive and prolonged use of nasal spray, but can also occur without a clear cause. Patients with chronic rhinitis usually have difficulty breathing through the nose, experience resistance when talking or during physical exertion, and have impaired sleep quality. If the cause is not allergic, there has been no existing treatment – until now. Chordate’s Ozilia® treatment provides significant relief to more than half of all patients with chronic rhinitis. The treatment is already available for sale in selected EU markets and Saudi Arabia.
In a interview with Biostock, principal investigator Dr. Lino Di Rienzo Businco discusses the study titled “Effectiveness of Kinetic Oscillation Stimulation Treatment in Persistent Moderate-Severe Allergic Rhinitis Compared to Medical Therapy“. The study shows that Chordate’s Ozilia treatment improves nasal airflow more effectively than medical therapy alone in cases of persistent moderate to severe allergic rhinitis. Dr. Businco is an otolaryngologist, an expert in sports medicine, and has been treating patients with Ozilia for several years, including top athletes in Italy’s Olympic team.
“Key take away is the capability of Ozilia to complete the effectiveness of the standard medical care for allergic rhinitis with a very effective, non-invasive treatment and high patient compliance. Nasal obstruction, runny nose, nasal discharge, itching, and sneezing are better controlled when adding an effective treatment against neurogenic inflammation. Otherwise, symptoms are not always well controlled in this special group of patients with moderate to severe allergic rhinitis,” says Dr. Businco to Biostock.
Chordate Medical has not previously investigated the effects of Ozilia on allergic rhinitis to a significant extent, which means that the study results open up new potential opportunities for the company.
“The innovative concept is that Ozilia not only has a positive effect on non-allergic patients, but even on allergic patients in an effective way to better control the symptoms and improve the efficiency of standard drugs such as nasal sprays, steroid sprays, and antihistamines, and perhaps even reduce the need for these medications with their associated side effects”, says Dr. Businco.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia®, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
